RNA
The acquisition will allow Tempus to expand its technical team and create a stronger presence in digital pathology.
The collaboration will leverage Genetic Leap's RNA-targeted AI platform to create genetic medicines against selected targets.
Synthace also announced a new addition to its board of directors.